The clinical pharmacokinetics of parecoxib in Chinese patients
Chenghai Wang
Abstract
Chenghai Wang
Abstract
Objective To study the clinical pharmacokinetics of parecoxib in Chinese patients. Methods Twelve patients with ASA Ⅰ orⅡ undergoing elective surgery were injected parecoxib 40 mg.Blood samples were collected at 10 , 20 , 30 , 40 , 50and 60min , and 1.5 , 2 , 4 , 6 , 8 , 12 , 16 , 20 and 24hafter injection.The plasma concentration of parecoxib and its product valdecoxib were measured with high-performance liquid chromatography.The pharmacokinetic parameters were calculated with 3P97software package.Results The clinical pharmacokinetics of parecoxib is fitted to a two-compartment model.The main pharmacokinetic parameter including Cmax was ( 31.58±13.41 ) and ( 0.91±0.21 ) μ g / ml , Tmax was ( 10.00±0.00 ) min and ( 24.00±14.30 ) min , and t 1 / 2 β was ( 1.06±0.92 ) h and ( 10.65±3.20 ) h , respectively.Conclusion The clinical pharmacokinetics of parecoxib fits to a two-compartment model in Chinese patients.
OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Objective To study the clinical pharmacokinetics of parecoxib in Chinese patients. Methods Twelve patients with ASA Ⅰ orⅡ undergoing elective surgery were injected parecoxib 40 mg.Blood samples were collected at 10 , 20 , 30 , 40 , 50and 60min , and 1.5 , 2 , 4 , 6 , 8 , 12 , 16 , 20 and 24hafter injection.The plasma concentration of parecoxib and its product valdecoxib were measured with high-performance liquid chromatography.The pharmacokinetic parameters were calculated with 3P97software package.Results The clinical pharmacokinetics of parecoxib is fitted to a two-compartment model.The main pharmacokinetic parameter including Cmax was ( 31.58±13.41 ) and ( 0.91±0.21 ) μ g / ml , Tmax was ( 10.00±0.00 ) min and ( 24.00±14.30 ) min , and t 1 / 2 β was ( 1.06±0.92 ) h and ( 10.65±3.20 ) h , respectively.Conclusion The clinical pharmacokinetics of parecoxib fits to a two-compartment model in Chinese patients.
Key concepts: Parecoxib, Valdecoxib, Pharmacokinetics, Medicine, Cmax, Plasma concentration, Anesthesia, Pharmacology